Who are fentanyl and dexmedetomindine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fentanyl-and-dexmedetomindine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

fentanyl and dexmedetomindine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

fentanyl and dexmedetomindine (fentanyl and dexmedetomindine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist combined with alpha-2 adrenergic agonist. Area: Anesthesia, Analgesia, Sedation.

marketed Opioid agonist combined with alpha-2 adrenergic agonist Mu opioid receptor (fentanyl); Alpha-2 adrenergic receptor (dexmedetomidine) Anesthesia, Analgesia, Sedation Small molecule Live · refreshed every 30 min

Target snapshot

fentanyl and dexmedetomindine (fentanyl and dexmedetomindine) — The Affiliated Hospital of Qingdao University. Fentanyl is an opioid agonist that binds mu opioid receptors for analgesia and sedation, while dexmedetomidine is an alpha-2 adrenergic agonist that provides additional sedation and analgesia with reduced respiratory depression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
fentanyl and dexmedetomindine TARGET	fentanyl and dexmedetomindine	The Affiliated Hospital of Qingdao University	marketed	Opioid agonist combined with alpha-2 adrenergic agonist	Mu opioid receptor (fentanyl); Alpha-2 adrenergic receptor (dexmedetomidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist combined with alpha-2 adrenergic agonist class)

The Affiliated Hospital of Qingdao University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fentanyl and dexmedetomindine — Competitive Intelligence Brief. https://druglandscape.com/ci/fentanyl-and-dexmedetomindine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab